These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 34169322)
1. SP2509, an inhibitor of LSD1, exerts potential antitumor effects by targeting the JAK/STAT3 signaling. Zhen H; Zhang X; Zhang L; Zhou M; Lu L; Wu L; He N; Wang J; Li R; Guo Y Acta Biochim Biophys Sin (Shanghai); 2021 Jul; 53(8):1098-1105. PubMed ID: 34169322 [TBL] [Abstract][Full Text] [Related]
2. LSD1 (KDM1A)-independent effects of the LSD1 inhibitor SP2509 in cancer cells. Sonnemann J; Zimmermann M; Marx C; Ebert F; Becker S; Lauterjung ML; Beck JF Br J Haematol; 2018 Nov; 183(3):494-497. PubMed ID: 29205263 [No Abstract] [Full Text] [Related]
3. SP2509, a Selective Inhibitor of LSD1, Suppresses Retinoblastoma Growth by Downregulating β-catenin Signaling. Jiang A; Wu W; Xu C; Mao L; Ao S; Guo H; Sun X; Tao J; Sang Y; Huang G Invest Ophthalmol Vis Sci; 2022 Mar; 63(3):20. PubMed ID: 35297943 [TBL] [Abstract][Full Text] [Related]
4. A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cells. Kim BH; Yin CH; Guo Q; Bach EA; Lee H; Sandoval C; Jayabose S; Ulaczyk-Lesanko A; Hall DG; Baeg GH Mol Cancer Ther; 2008 Sep; 7(9):2672-80. PubMed ID: 18790749 [TBL] [Abstract][Full Text] [Related]
5. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Fiskus W; Sharma S; Shah B; Portier BP; Devaraj SG; Liu K; Iyer SP; Bearss D; Bhalla KN Leukemia; 2014 Nov; 28(11):2155-64. PubMed ID: 24699304 [TBL] [Abstract][Full Text] [Related]
6. Zelnorm, an agonist of 5-Hydroxytryptamine 4-receptor, acts as a potential antitumor drug by targeting JAK/STAT3 signaling. Zhang L; Song Q; Zhang X; Li L; Xu X; Xu X; Li X; Wang Z; Lin Y; Li X; Li M; Su F; Wang X; Qiu P; Guan H; Tang Y; Xu W; Yang J; Zhao C Invest New Drugs; 2020 Apr; 38(2):311-320. PubMed ID: 31087223 [TBL] [Abstract][Full Text] [Related]
7. Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells. Chen X; Du Y; Nan J; Zhang X; Qin X; Wang Y; Hou J; Wang Q; Yang J PLoS One; 2013; 8(5):e63697. PubMed ID: 23704931 [TBL] [Abstract][Full Text] [Related]
8. MiR-340 affects gastric cancer cell proliferation, cycle, and apoptosis through regulating SOCS3/JAK-STAT signaling pathway. Xiao C; Hong H; Yu H; Yuan J; Guo C; Cao H; Li W Immunopharmacol Immunotoxicol; 2018 Aug; 40(4):278-283. PubMed ID: 29658372 [TBL] [Abstract][Full Text] [Related]
9. Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution. Bharadwaj U; Kasembeli MM; Robinson P; Tweardy DJ Pharmacol Rev; 2020 Apr; 72(2):486-526. PubMed ID: 32198236 [TBL] [Abstract][Full Text] [Related]
10. 17-hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently cross-linking Janus kinases and induces apoptosis of human cancer cells. Wang Y; Ma X; Yan S; Shen S; Zhu H; Gu Y; Wang H; Qin G; Yu Q Cancer Res; 2009 Sep; 69(18):7302-10. PubMed ID: 19706767 [TBL] [Abstract][Full Text] [Related]
11. Novel small molecular inhibitors disrupt the JAK/STAT3 and FAK signaling pathways and exhibit a potent antitumor activity in glioma cells. Swiatek-Machado K; Mieczkowski J; Ellert-Miklaszewska A; Swierk P; Fokt I; Szymanski S; Skora S; Szeja W; Grynkiewicz G; Lesyng B; Priebe W; Kaminska B Cancer Biol Ther; 2012 Jun; 13(8):657-70. PubMed ID: 22555804 [TBL] [Abstract][Full Text] [Related]
12. Discovery and evaluation of Atopaxar hydrobromide, a novel JAK1 and JAK2 inhibitor, selectively induces apoptosis of cancer cells with constitutively activated STAT3. Sun J; Du Y; Zhang X; Wang Z; Lin Y; Song Q; Wang X; Guo J; Li S; Nan J; Yang J Invest New Drugs; 2020 Aug; 38(4):1003-1011. PubMed ID: 31612426 [TBL] [Abstract][Full Text] [Related]
13. SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation. Duan Z; Bradner JE; Greenberg E; Levine R; Foster R; Mahoney J; Seiden MV Clin Cancer Res; 2006 Nov; 12(22):6844-52. PubMed ID: 17121906 [TBL] [Abstract][Full Text] [Related]
14. Physalin A exerts anti-tumor activity in non-small cell lung cancer cell lines by suppressing JAK/STAT3 signaling. Zhu F; Dai C; Fu Y; Loo JF; Xia D; Gao SP; Ma Z; Chen Z Oncotarget; 2016 Feb; 7(8):9462-76. PubMed ID: 26843613 [TBL] [Abstract][Full Text] [Related]
15. 6-Bromoindirubin-3'-oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells. Liu L; Nam S; Tian Y; Yang F; Wu J; Wang Y; Scuto A; Polychronopoulos P; Magiatis P; Skaltsounis L; Jove R Cancer Res; 2011 Jun; 71(11):3972-9. PubMed ID: 21610112 [TBL] [Abstract][Full Text] [Related]
16. Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases. Murone M; Vaslin Chessex A; Attinger A; Ramachandra R; Shetty SJ; Daginakatte G; Sengupta S; Marappan S; Dhodheri S; Rigotti S; Bachhav Y; Brienza S; Traxler P; Lang M; Aguet M; Zoete V; Michielin O; Nicholas C; Johnson FM; Ramachandra M; McAllister A Mol Cancer Ther; 2016 Oct; 15(10):2334-2343. PubMed ID: 27439479 [TBL] [Abstract][Full Text] [Related]
17. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Blaskovich MA; Sun J; Cantor A; Turkson J; Jove R; Sebti SM Cancer Res; 2003 Mar; 63(6):1270-9. PubMed ID: 12649187 [TBL] [Abstract][Full Text] [Related]
18. In vivo and in vitro effects of microRNA-221 on hepatocellular carcinoma development and progression through the JAK-STAT3 signaling pathway by targeting SOCS3. Huang S; Zhou D; Li YX; Ming ZY; Li KZ; Wu GB; Chen C; Zhao YN J Cell Physiol; 2019 Apr; 234(4):3500-3514. PubMed ID: 30370582 [TBL] [Abstract][Full Text] [Related]
19. Curcumin-Mediated Apoptotic Cell Death in Papillary Thyroid Cancer and Cancer Stem-Like Cells through Targeting of the JAK/STAT3 Signaling Pathway. Khan AQ; Ahmed EI; Elareer N; Fathima H; Prabhu KS; Siveen KS; Kulinski M; Azizi F; Dermime S; Ahmad A; Steinhoff M; Uddin S Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936675 [TBL] [Abstract][Full Text] [Related]
20. ECPIRM, a Potential Therapeutic Agent for Cutaneous T-Cell Lymphoma, Inhibits Cell Proliferation and Promotes Apoptosis via a JAK/STAT Pathway. Yang H; Ma P; Cao Y; Zhang M; Li L; Wei J; Tao L; Qian K Anticancer Agents Med Chem; 2018; 18(3):401-411. PubMed ID: 28356009 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]